Axsome Therapeutics Stock Performance
| AXSM Stock | USD 185.96 1.02 0.55% |
On a scale of 0 to 100, Axsome Therapeutics holds a performance score of 13. The firm shows a Beta (market volatility) of -0.39, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Axsome Therapeutics are expected to decrease at a much lower rate. During the bear market, Axsome Therapeutics is likely to outperform the market. Please check Axsome Therapeutics' expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Axsome Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Axsome Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Axsome Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 386.2 M | |
| Total Cashflows From Investing Activities | -270 K |
Axsome Therapeutics Relative Risk vs. Return Landscape
If you would invest 13,468 in Axsome Therapeutics on October 27, 2025 and sell it today you would earn a total of 5,128 from holding Axsome Therapeutics or generate 38.08% return on investment over 90 days. Axsome Therapeutics is currently generating 0.5747% in daily expected returns and assumes 3.4406% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Axsome, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Axsome Therapeutics Target Price Odds to finish over Current Price
The tendency of Axsome Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 185.96 | 90 days | 185.96 | roughly 2.42 |
Based on a normal probability distribution, the odds of Axsome Therapeutics to move above the current price in 90 days from now is roughly 2.42 (This Axsome Therapeutics probability density function shows the probability of Axsome Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Axsome Therapeutics has a beta of -0.39. This suggests as returns on the benchmark increase, returns on holding Axsome Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Axsome Therapeutics is likely to outperform the market. Additionally Axsome Therapeutics has an alpha of 0.5915, implying that it can generate a 0.59 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Axsome Therapeutics Price Density |
| Price |
Predictive Modules for Axsome Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Axsome Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Axsome Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Axsome Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Axsome Therapeutics is not an exception. The market had few large corrections towards the Axsome Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Axsome Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Axsome Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.59 | |
β | Beta against Dow Jones | -0.39 | |
σ | Overall volatility | 16.26 | |
Ir | Information ratio | 0.14 |
Axsome Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Axsome Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Axsome Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Axsome Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 385.69 M. Net Loss for the year was (287.22 M) with profit before overhead, payroll, taxes, and interest of 515.6 M. | |
| Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Over 77.0% of the company shares are held by institutions such as insurance companies |
Axsome Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Axsome Stock often depends not only on the future outlook of the current and potential Axsome Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Axsome Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 47.9 M | |
| Cash And Short Term Investments | 315.4 M |
Axsome Therapeutics Fundamentals Growth
Axsome Stock prices reflect investors' perceptions of the future prospects and financial health of Axsome Therapeutics, and Axsome Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Axsome Stock performance.
| Return On Equity | -2.75 | |||
| Return On Asset | -0.2 | |||
| Profit Margin | (0.41) % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 9.27 B | |||
| Shares Outstanding | 50.41 M | |||
| Price To Earning | (3.34) X | |||
| Price To Book | 127.15 X | |||
| Price To Sales | 16.70 X | |||
| Revenue | 385.69 M | |||
| EBITDA | (272.6 M) | |||
| Cash And Equivalents | 73.39 M | |||
| Cash Per Share | 1.82 X | |||
| Total Debt | 192.96 M | |||
| Debt To Equity | 6.20 % | |||
| Book Value Per Share | 1.47 X | |||
| Cash Flow From Operations | (128.41 M) | |||
| Earnings Per Share | (4.67) X | |||
| Total Asset | 568.5 M | |||
| Retained Earnings | (1.12 B) | |||
| Current Asset | 34.76 M | |||
| Current Liabilities | 6.74 M | |||
About Axsome Therapeutics Performance
By examining Axsome Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Axsome Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Axsome Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 198 people.Things to note about Axsome Therapeutics performance evaluation
Checking the ongoing alerts about Axsome Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Axsome Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Axsome Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 385.69 M. Net Loss for the year was (287.22 M) with profit before overhead, payroll, taxes, and interest of 515.6 M. | |
| Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Over 77.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Axsome Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Axsome Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Axsome Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Axsome Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Axsome Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Axsome Therapeutics' stock. These opinions can provide insight into Axsome Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.